SecBot SecBot
6-K ·Filed Oct 26, 2026

OPTH

Optimi Health Corp.
NEUTRAL
Impact 3/10
Processed1h 9m ago SEC0001171843-26-006808
Notable filing: 6-K

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-006808
Document: f6k_102626.htm0001171843-26-006808
Document: 0001171843-26-006808-index-headers.html0001171843-26-006808
Document: 0001171843-26-006808-index.html0001171843-26-006808
Document: 0001171843-26-006808.txt0001171843-26-006808
24 reports for OPTH
Performance horizon
30% Hit rate @ T+5 3 of 10 directional calls Went positive at some point 4 of 10 best @ T+5▲ +10.22%Sep 10, 2026
Filters
Rows
Reports for OPTH — sortable, filterable
TypeNow
Oct 26, 2026
today
6-K
NEUTRAL ★ 3/10
$3.36awaiting T+5—$3.25 (−3.27%)
Oct 20, 2026
6d ago
6-K
NEUTRAL ★ 4/10
$3.36awaiting T+5—$3.25 (−3.27%)
Oct 7, 2026
19d ago
6-K
NEUTRAL ★ 2/10
$4.04 $3.17▼ −21.66%▼ −20.68%$3.25 (−19.55%)
Oct 5, 2026
20d ago
SC 13G/A
NEUTRAL ★ 3/10
$4.13 $3.50▼ −15.25%▼ −15.12%$3.25 (−21.31%)
Sep 29, 2026
27d ago
6-K
NEUTRAL ★ 2/10
$4.78 $4.13▼ −13.60%▼ −15.55%$3.25 (−32.01%)
Sep 23, 2026
4w ago
6-K
NEUTRAL ★ 3/10
$4.96 $4.71▼ −5.04%▼ −4.37%$3.25 (−34.48%)
Sep 22, 2026
4w ago
6-K
NEUTRAL ★ 3/10
$4.96 $4.78▼ −3.63%▼ −2.44%$3.25 (−34.48%)
Sep 16, 2026
5w ago
6-K
BULLISH ★ 6/10
$4.90 $4.96▲ +1.22%▼ −0.60%$3.25 (−33.67%)
Sep 10, 2026
6w ago
6-K
BULLISH ★ 5/10
$4.50 $4.96▲ +10.22%▲ +10.72%$3.25 (−27.78%)
Aug 26, 2026
8w ago
6-K
BEARISH ★ 6/10
$4.89 $4.70▲ +3.89%▲ +4.15%$3.25 (+33.54%)
Showing 10 of 24

US Market Status

Market Closed — Opens in 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh OPTH Intelligence

Analysis is for subscribers only.

Optimi Health Corp. announced the establishment of a wholly owned Australian subsidiary, Optimi Australia Pty Ltd, to handle distribution and business development, and appointed Adrian Jones (former Bristol Myers Squibb executive) as Director of Australian Operations. The subsidiary will sell the…

Subscribe for Full Access